PTC Therapeutics - PTCT Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PTCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PTCT, but not buy additional shares or sell existing shares.
View PTCT analyst ratings or view top-rated stocks.

10 Wall Street analysts have issued 1 year price targets for PTC Therapeutics' stock. Their PTCT share price forecasts range from $38.00 to $76.00. On average, they expect the company's stock price to reach $56.30 in the next year. This suggests a possible upside of 10.8% from the stock's current price.
View analysts price targets for PTCT or view top-rated stocks among Wall Street analysts.

PTC Therapeutics' stock was trading at $39.83 at the start of the year. Since then, PTCT shares have increased by 27.5% and is now trading at $50.79.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our PTCT earnings forecast.

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced its quarterly earnings results on Thursday, August, 4th. The biopharmaceutical company reported ($2.13) EPS for the quarter, missing the consensus estimate of ($1.67) by $0.46. The biopharmaceutical company had revenue of $165.50 million for the quarter, compared to analyst estimates of $162.53 million. PTC Therapeutics had a negative net margin of 89.89% and a negative trailing twelve-month return on equity of 983.21%. The company's revenue was up 41.8% on a year-over-year basis. During the same period in the previous year, the company posted ($1.68) earnings per share.

PTC Therapeutics issued an update on its FY 2022 earnings guidance on Thursday, August, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $700.00 million-$750.00 million, compared to the consensus revenue estimate of $722.95 million.

24 employees have rated PTC Therapeutics Chief Executive Officer Stuart W. Peltz on Glassdoor.com. Stuart W. Peltz has an approval rating of 77% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Cisco Systems (CSCO), Regulus Therapeutics (RGLS), Aduro Biotech (ADRO) and Gilead Sciences (GILD).

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PTCT stock can currently be purchased for approximately $50.79.

PTC Therapeutics (NASDAQ:PTCT) has a market capitalization of $3.63 billion and generates $538.59 million in revenue each year. The biopharmaceutical company earns $-523,900,000.00 in net income (profit) each year or ($7.83) on an earnings per share basis.

The company employs 1,177 workers across the globe.

PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The official website for the company is www.ptcbio.com. The biopharmaceutical company can be reached via phone at (908) 222-7000, via email at ehill@ptcbio.com, or via fax at 908-222-7231.